Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open and free access to select preclinical-stage molecules.

The platform, opn.ME, comprises 19 compounds that Boehringer has deemed suitable for preclinical in vivo proof-of-concept studies. The compounds target a diverse set of proteins implicated in a range of indications, including B cell CLL lymphoma 6 (BCL6); CC chemokine receptor 1 (CCR1; CD191); spleen tyrosine kinase (SYK); fatty acid synthase (FASN; FAS); HCV proteins; and others...